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Abstract. 
 
The middle T antigen of murine Polyomavi-
rus (PymT) rapidly transforms endothelial cells, leading 
to the formation of vascular tumors in newborn mice. 
Transformed endothelial (End.) cell lines established 
from such tumors exhibit altered proteolytic activity as 
a result of increased expression of urokinase-type plas-
minogen activator (uPA) and are capable of inducing 
vascular tumors efficiently when injected into adult 
mice. In this study we have used mice lacking compo-
nents of the PA/plasmin system to analyze the role of 
this system in the transformation process and in tumor 
growth. We found that the proteolytic status of the host 
is not a critical determinant for PymT-induced vascular 
tumor formation. In addition, the lack of either uPA or 
tissue-type PA (tPA) activity is not limiting for the es-
tablishment and proliferation of End. cells in vitro, al-
though the combined loss of both PA activities leads to 
a marked reduction in proliferation rates. Furthermore, 
the in vitro morphogenetic properties of mutant End. 
cells in fibrin gels could only be correlated with an al-
tered proteolytic status in cells lacking both uPA and 
tPA. However, in contrast with tumors induced by 
PymT itself, the tumorigenic potential of mutant and 
wild-type End. cell lines was found to be highly depen-
dent on the proteolytic status of both the tumor cells 
and the host. Thus, genetic alterations in the PA/plas-
min system affect vascular tumor development, indicat-
ing that this system is a causal component in PymT-
mediated oncogenesis.
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Molecular Pathology, University of Vienna, A-1030 Vienna, Austria. Tel.:
43-1-798-7153. Fax: 43-1-797-30-630.
 
1. 
 
Abbreviations used in this paper
 
:
 
 
 
End., endothelioma; MMP, matrix
metalloproteinase; PA, plasminogen activator; uPA, urokinase-type PA;
uPAR, uPA receptor; tPA, tissue-type PA; PAI, PA inhibitor; Plg, plasmi-
nogen; PTAH, phosphotungstic acidÐhemotoxylin; PymT, Polyoma mid-
dle T antigen.
 
O
 
ncogenesis
 
 is a multistep process that requires a
long latency period between the initiating event
and the appearance of the tumor. However, a few
viral oncogenes are known to rapidly transform target tis-
sues without the need for additional genetic events; one
such viral oncogene is the Polyoma middle T antigen
(PymT).
 
1
 
 The PymT antigen specifically transforms prolif-
erating endothelial cells apparently in a single-step man-
ner, resulting in the formation of hemorrhagic cystic tu-
mors in embryonic and neonatal mice, but not in adult mice
where endothelial cell proliferation has ceased (for review
see Pepper et al., 1997). The potency with which PymT
transforms endothelial cells is thought to be a conse-
quence of its interaction with proteins of the signal trans-
duction machinery (for review see Brizuela et al., 1994;
Kiefer et al., 1994
 
a
 
). These tumors are functionally remi-
niscent of human vascular tumors in that they are endo-
thelial specific and organ nonspecific (for review see Wagner
and Risau, 1994; Pepper et al., 1997), and that tumor-bear-
ing mice develop features of the Kasabach-Merritt syn-
drome, i.e., thrombocytopenia, anemia, and associated
splenomegaly (Dubois-Stringfellow et al., 1994
 
a
 
). 
Tumor formation and subsequent invasion involve the
disruption of anatomical barriers including basement
membranes and penetration of tumor cells into normal ad-
jacent tissues. Several lines of evidence indicate that en-
hanced invasive and metastatic potential is correlated with
increased protease activity. It has been shown that both tu-
mor and stromal cells express enzymes that degrade com-
ponents of the extracellular matrix. Many of the relevant
enzymes belong to one of two families: the serine pro-
teases, in particular the plasminogen activator (PA)/plasmin
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system, and the matrix metalloproteinases (MMPs). Uroki-
nase and tissue-type PAs (uPA and tPA) are the principal
activators of plasminogen (Plg), the zymogen from which
plasmin is derived. uPA is secreted in the form of an inac-
tive precursor that binds with high affinity to a specific gly-
cosylphosphatidylinositol-anchored cell surface receptor.
Plasmin is a protease of tryptic specificity that either di-
rectly, or indirectly through the activation of latent MMPs,
hydrolyzes extracellular proteins. The existence of multiple
specific physiological inhibitors of both plasmin, i.e., 
 
a
 
2
 
-
antiplasmin, and PAs, i.e., PA inhibitors 1 and 2 (PAI-1
and PAI-2), provides additional points of regulation along
this protease cascade (for review see Dan¿ et al., 1985; Vas-
salli et al., 1991; Pepper et al., 1996).
The recent advent of mice lacking uPA, uPA receptor
(uPAR), tPA, PAI-1, and Plg has questioned much early
dogma concerning the role of the PA/plasmin system in
processes requiring extracellular matrix breakdown. Thus,
uPA
 
2
 
/
 
2
 
, tPA
 
2
 
/
 
2
 
, and uPA
 
2
 
/
 
2 
 
and tPA
 
2
 
/
 
2
 
(utPA
 
2
 
/
 
2
 
)
mice, as well as Plg
 
2
 
/
 
2 
 
mice, develop normally in utero
and are fertile. However, utPA
 
2
 
/
 
2
 
 mice develop multiple
organ failure starting at 2Ð3 mo of age as a result of exten-
sive extravascular fibrin accumulation as well as general-
ized microvascular thrombosis (Carmeliet et al., 1994).
utPA
 
2
 
/
 
2
 
 mice thus have retarded postnatal growth, ex-
hibit reduced fertility, and have a shortened life span. A
similar phenotype is observed in Plg-deficient mice
(Bugge et al., 1995
 
a
 
; Ploplis et al., 1995). The phenotype of
both utPA
 
2
 
/
 
2
 
 and Plg-deficient mice therefore appears
to be due to a systemic defect in fibrinolysis. Although no
overt phenotypic alterations have been observed in
uPAR
 
2
 
/
 
2
 
 mice with respect to development, fertility,
and homeostasis (Bugge et al., 1995
 
b
 
), it has recently
been reported that adult mice with a combined deficiency
in tPA and uPAR display hepatic sinusoidal fibrin depos-
its, demonstrating that uPAR plays a role in physiological
fibrinolysis (Bugge et al., 1996). Finally, development and
fertility are unaffected in PAI-1Ðdeficient mice, although
the absence of PAI-1 induces a mild hyperfibrinolytic state
(Carmeliet et al., 1993
 
a,b
 
). Therefore, neither PAs nor Plg
are essential for mouse development, postnatal growth, or
fertility, suggesting that the primary role for the PA/plas-
min system in the mouse is fibrinolysis.
In previous studies with PymT-transformed endothelial
(End.) cell lines in a fibrin gel system, we observed that
End. cells formed cystlike structures rather than capillary-
like tubes, which correlated with their increased proteo-
lytic activity (Montesano et al., 1990). Reduction of pro-
tease activity by the addition of broad spectrum serine
protease inhibitors led to the formation of capillary-like
tubes, resulting in the hypothesis that tightly controlled ex-
tracellular proteolysis is essential for normal capillary mor-
phogenesis (Pepper and Montesano, 1990). Further sup-
port for the role of the PA/plasmin system in aberrant
morphogenesis in vitro came from experiments in which
depletion of Plg from serum or addition of neutralizing an-
tibodies to murine uPA inhibited cyst formation (Dubois-
Stringfellow et al., 1994
 
b
 
). These findings implicated in-
creased proteolysis, and in particular increased uPA activ-
ity, in aberrant vascular morphogenesis in vitro and fur-
ther suggested a causal role for PymT in the elevated
proteolytic activity of End. cells. In this study, mice lacking
uPA, tPA, utPA, PAI-1, or Plg were used to investigate
whether the PA/plasmin system might be important for
PymT- or End. cellÐinduced tumor formation.
 
Materials and Methods
 
Mice
 
The generation of uPA
 
2
 
/
 
2
 
, tPA
 
2
 
/
 
2
 
, uPA,tPA
 
2
 
/
 
2
 
 (utPA
 
2
 
/
 
2
 
), PAI-
1
 
2
 
/
 
2
 
, and Plg
 
2
 
/
 
2
 
 mice has been described (Carmeliet et al., 1993
 
a
 
, 1994;
Ploplis et al., 1995). All mice in a C57Bl6/129 background were propa-
gated by brotherÐsister matings and have been interbred for more than six
generations. CD1 nude mice were purchased from CharlesRiver (Sulzfeld,
Germany).
 
Virus Induced Tumor Induction in Neonatal Mice
 
Helper-free stocks of the N-TKmT virus were obtained from the viral pro-
ducer cell line GP+E subclone 108.4.2 as described previously (Williams
et al., 1988). Neonatal mice of various genotypes were injected intraperi-
toneally with 1Ð2.5
 
 3 
 
10
 
5
 
 neo
 
R
 
-transferring particles. The mice were ob-
served carefully and analyzed as soon as the first mouse of an injected lit-
ter showed signs of anemia.
 
Derivation and Maintenance of End. Cells
 
Macroscopically visible tumors from mice injected with PymT viral parti-
cles were explanted, and End. cell lines were established as previously de-
scribed (Kiefer et al., 1994
 
b
 
). End. cells could be established with relative
ease from heterogeneously growing primary cultures, since they outgrow
contaminating fibroblasts. Within 5Ð10 passages, a homogeneously grow-
ing, mostly clonal population of End. cells was obtained, which was used
for the experiments described. Cell lines were maintained in DME supple-
mented with 5% FCS, glutamine, and nonessential amino acids and sub-
cultured at confluence every 4Ð8 d. The origin and nomenclature of these
cell lines are summarized in Table I. 
 
Determination of Proliferation Rates of End. Cells
 
End. cells were plated at a density of 4
 
 3 
 
10
 
5
 
Ð1
 
 3 
 
10
 
6
 
 per 25-cm
 
2
 
 flask,
counted, and replated at the same density every 6Ð8 d. Total cumulative
cell numbers are represented over 23 d in culture.
 
Tumor Induction by Injection of End. Cells in
Adult Mice
 
For the induction of End. cellÐinduced tumors, C57Bl6/129 wild-type and
mutant mice, derived from brotherÐsister matings and interbred for more
than six generations (10Ð14 wk old), and CD1 nude mice (8Ð10 wk old)
were injected subcutaneously into the flanks of the right leg with 1.5Ð2
 
 3
 
10
 
6
 
 cells, and then scored for tumor formation. The times taken for the on-
set of tumors and the latency period to form tumors of 125 mm
 
2
 
 (maxi-
mum size) were recorded. All mice were killed when they had 125-mm
 
2
 
tumors. The observation period was until 60 d after injection.
 
Northern Blot Hybridization
 
RNA analyses were carried out using standard Northern techniques
(Kiefer et al., 1994
 
b
 
). The probes were kindly provided by D. Belin (Uni-
versity of Geneva, Switzerland) (uPA), S. Strickland (State University of
New York, Stony Brook) (tPA), and R. Bravo (Bristol-Myers Squibb
Pharmaceutical Research Institute, Princeton, NJ) (PAI-1).
 
Immunohistochemical Analysis
and Immunocytochemistry
 
Tissue specimens were explanted, dissected, fixed overnight in 4%
paraformaldehyde in PBS, and embedded in paraffin; 5-
 
m
 
m-thick sections
were stained with hematoxylin and eosin. Adjacent sections were used for
immunocytochemical reactions with antibody against factor VIIIÐrelated
antigen/von Willebrand factor (vWF) (Dakopatts, Copenhagen, Den- 
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mark). Some sections were processed using special staining techniques for
fibrin. These included the Lendrum (Lendrum et al., 1962) and MalloryÕs
phosphotungstic acidÐhematoxylin (PTAH) techniques.
 
Zymography and Reverse Zymography
 
Confluent monolayers of End. cells in 35-mm tissue-culture dishes were
washed twice with serum-free DME, and 1.5 ml serum-free DME contain-
ing 200 KIU/ml Trasylol (Bayer AG, Zurich, Switzerland) was added. 15 h
later, cell extracts and culture supernatants were prepared and analyzed
by zymography and reverse zymography as previously described (Vassalli
et al., 1984; Montesano et al., 1990). Cell number was determined in a sec-
ond set of dishes processed in parallel, and cell extract and culture super-
natant samples were analyzed on the basis of cell equivalents.
 
In Vitro Fibrin Gel Assay
 
End. cells were seeded in suspension into 500-
 
m
 
l fibrin gels at 1 
 
3
 
 10
 
4
 
 cells
per gel. 500 
 
m
 
l DME containing 10% FCS was added to each well above
the fibrin gels. Fibrin gels were prepared as previously described (Monte-
sano et al., 1990). All experiments were performed in the absence or pres-
ence of 200 KIU/ml Trasylol, which was added both to the gel and to the
medium at the time of embedding. Medium (
 
6
 
Trasylol) was renewed ev-
ery 2Ð3 d. Between 4 and 16 d after seeding, cultures were fixed in situ
overnight in 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4, and
photographed using a Phase Contrast-2 microscope (Nikon Inc., Garden
City, NY).
 
Results
 
PymT Efficiently Induces Vascular Tumors
in the Absence of Individual Components of the
PA/Plasmin System 
 
To determine if PA/plasmin-dependent proteolytic activ-
ity is an essential requirement for the formation of vascu-
lar tumors by PymT, we inoculated newborn mice lacking
uPA, tPA, utPA, PAI-1, or Plg with the PymT transducing
retrovirus N-TkmT (Williams et al., 1988). The frequency
of tumor formation was almost 100% in all mutant mice
tested, and the time required for the development of lethal
tumors (latency) varied only slightly (Table I). The high
penetrance in Plg
 
2
 
/
 
2
 
 mice was unexpected and no delay
or inhibition of tumor formation was observed. Most mice
were terminally ill within 8Ð10 d, and only the double-
mutant pups lacking uPA and tPA succumbed after a
slightly longer period of 12Ð14 d (Table I). These utPA
 
2
 
/
 
2
 
tumors retained the characteristic morphologic proper-
ties of PymT-induced tumors (Fig. 1, 
 
A
 
 and 
 
B
 
). All tumors
appeared as blood-filled/hemorrhagic cysts lined by endo-
thelial cells and were not different from similar tumors in-
duced by PymT in control mice (Kiefer et al., 1994
 
b
 
). Rep-
resentative sections through a typical lesion that formed in
a double mutant (utPA
 
2
 
/
 
2
 
) mouse as well as in a Plg
 
2
 
/
 
2
 
mouse are shown in Fig. 1. Staining with anti-vWF anti-
body shows endothelial cells lining these cysts (Fig. 1 
 
B
 
).
These results indicate that the PA/plasmin-dependent pro-
teolytic status of the host is apparently not a critical deter-
minant in the transformation of endothelial cells by PymT
and in the formation of vascular tumors in newborn mice.
Figure 1. PymT virusÐinduced vascular tumors in newborn mice lacking utPA (A and B) and Plg (C). H/E (A and C) and vWF (B)
staining is shown. (Arrowheads) Endothelial cells lining the tumors. Bar, 50 mm.
 
Table I. Vascular Tumors Induced by PymT Virus and 
Establishment of End. Cell Lines
 
Tumors End. cell lines
Genotype Latency Penetrance Name Abbr. Origin
 
d
 
wt
 
1
 
/
 
1
 
8Ð10 29/30 bEnd.1 b1 brain
eEnd.2 e2 yolk sac
mEnd.3 m3 mesentery
sEnd.1 s1 skin
sEnd.2 s2 skin thorax
uPA
 
2
 
/
 
2
 
10Ð13 9/10 mEnd.u23 u23 mesentery
sEnd.u24 u24 skin thorax
tPA
 
2
 
/
 
2
 
11Ð13 8/8 mEnd.t37 t37 mesentery
pEnd.t38 t38 pancreas
uPA
 
2
 
/2 tPA2/2 12Ð14 11/11 sEnd.ut1 ut1 skin sternum
liEnd.ut2 ut2 liver
PAI-12/2 6Ð8 3/3 luEnd.p1 p1 lung
liEnd.p3 p3 liver
Plg2/2 8Ð12 9/9 ND
Supernatants from PymT-producing fibroblasts were injected into newborn wild-type
and mutant mice, which were propagated by brotherÐsister matings. All mutant End.
cell lines were established from C57Bl/6 3 129 mice. The derivation of the wild-type
End. cell lines was previously described; for details regarding establishment, see Ma-
terials and Methods.The Journal of Cell Biology, Volume 137, 1997 956
Derivation of End. Cell Lines Lacking uPA, tPA, utPA, 
and PAI-1
We have previously established transformed End. cell
lines from tumor-bearing wild-type and various Src-kinase
mutant mice, as well as by infection of primary endothelial
cells by PymT in vitro (for review see Wagner and Risau,
1994; Pepper et al., 1997). To test whether the absence of
components of the PA/plasmin system affects the capacity
to establish permanent End. cell lines in vitro, we derived
a number of independent cell lines from tumors induced in
tPA-, uPA-, utPA-, and PAI-1Ðdeficient mice (Table I).
Each of these cell lines displayed the characteristic spin-
dle-shaped, highly refractile morphology that is typical of
endothelial cells (data not shown). The time required to
establish the different mutant cell lines as homogeneously
growing, characteristic End. cells was not significantly dif-
ferent using single knockout mice. However, the double
mutant utPA2/2 End. cells took three times as long to es-
tablish when compared with controls (data not shown). With
the exception of ut1 and ut2, all End. cell lines exhibited
roughly equivalent growth parameters in vitro as mea-
sured by cell doubling times after z10 passages (Fig. 2).
The proliferation rate of ut1 and ut2 cell lines was ,50%
of controls. All End. cell lines obtained expressed the en-
dothelial-specific tyrosine kinase receptor Flk-1 (Fig. 3 A)
and CD31/PECAM-1 (data not shown), confirming their
endothelial origin. Most of these cell lines were clonal,
since only one integration site for the provirus was de-
tected by Southern blotting (data not shown).
To verify the genotype and measure the proteolytic
Figure 2. Proliferation rate of End. cells. The following End. cells
were used for analysis of proliferation rates: e2 (wt), passage
number 36 (p36); t38, p28 (tPA2/2); u24, p32 (uPA2/2); p1,
p12 (PAI-12/2); ut1, p13 and ut2, p21 (utPA2/2). Total cumu-
lative cell numbers are represented over 23 d in culture.
Figure 3. Expression of mRNA (A) and zymographic analysis
(B) of End. cells lacking uPA, tPA, utPA, and PAI-1. (A) Poly
A1 RNA from the following cells were analyzed by Northern
analysis: b4, passage number 41 (p41); u23 (p12); u24 (p18); t37
(p22); t38 (p16); ut1 (p9); ut2 (p11); p1 (p28); and p3 (p20). (B)
The following End. cell extracts and culture supernatants were
analyzed by zymography (a and b) and reverse zymography (c) as
described in Materials and Methods: s2 (p29); u23 (p30); t37
(p31); ut1 (p19); ut2 (p17); and p1 (p27). (b) The same gel as
shown in a, incubated at 378C for a longer time period.
Table II. Proteolytic Activity and Morphogenetic Behavior of End. Cells Lacking uPA, tPA, utPA, and PAI-1
Genotype Cell lines uPA* tPA* PAI-1* Behavior in fibrin gelsà
wt1/1 b1, b3, e2, s2, m1, s1 111 11 1 Variably large to small cysts and tubes (n 5 39)
uPA2/2 u23, u24 2 1 11 Medium to small cysts and tubes (n 5 18)
tPA2/2 t37, t38 11 2 11 Small cysts and tubes (n 5 14)
uPA2/2, tPA2/2 ut1, ut2 2 2 111 No cysts and no tubes; isolated cells and network of cell cords (n 5 6)
PAI-12/2 p1, p3 111 111 2 Variably large to small cysts and network of cell cords (n 5 14)
*Semiquantitative estimate determined by zymography (uPA, tPA) and reverse zymography (PAI-1).
àCells grown in three-dimensional fibrin gels for 4Ð16 d in the absence of Trasylol; n 5 number of experiments.
111, high activity; 11, intermediate activity; 1, low activity.Sabapathy et al. PymT Oncogenesis and the Role of PA/Plasmin System 957
profile of mutant End. cells, RNA expression and zymo-
graphic analysis were performed. As shown in Fig. 3 A,
both uPA-deficient cell lines (u23 and u24) expressed tPA
at significant levels but no detectable uPA. The tPA-defi-
cient End. cells t37 and t38 had high levels of uPA and no
detectable tPA, whereas PAI-1 deficient cells expressed
either uPA (p3) or uPA and tPA (p1) at high levels, but no
PAI-1. As expected, the two End. cell lines lacking both
Figure 4. Morphogenetic behavior of mutant End. cells in three-dimensional fibrin gels. End. cells were seeded in suspension into three-
dimensional fibrin gels and photographed by phase-contrast microscopy after the times indicated. Unless otherwise indicated, cells were
grown in the absence of Trasylol. (A) b1 (p14) cells after 11 d in culture form a medium to largeÐsized cyst and a narrow tube (lumen in-
dicated by arrowheads) in close proximity in the same culture. (B) e2 (p11) cells after 7 d in culture form a large cyst; (inset) when grown
in the presence of Trasylol for 14 d, e2 (p13) cells form narrow tubes (lumen indicated by arrowheads) instead of cysts. (C) u23 (p27)
cells after 14 d in culture form a medium-sized cyst. (D) t38 (p22) cells after 6 d in culture form a tube-like structure; (inset) at higher
magnification, a lumen (arrowhead) is clearly visible. (E) ut1 (p25) cells after 14 d in culture form a network of cell cords apparently de-
void of a lumen; (inset) single isolated presumably nonproliferating ut1 (p27) cells are frequently observed in the same cultures. (F) p1
(p6) cells after 16 d in culture form a small cyst. Bar: (AÐF) 125 mm; (B, D, and E, insets) 63 mm.The Journal of Cell Biology, Volume 137, 1997 958
PAs only expressed PAI-1 (Fig. 3 A). Zymographic and
reverse zymographic analysis (Fig. 3 B and Table II) con-
firmed the genotype of the cells. Thus, uPA, tPA, and
PAI-1 activity was undetectable in cell lines derived from
the corresponding knockout mice. Although we previously
indicated that PAI-1 activity was undetectable by reverse
zymography in two wild-type End. cell lines, namely b1
and e2 (Montesano et al., 1990), in the four additional
wild-type cell lines assessed in this study, PAI-1 activity
was detected (data not shown). Similarly, PAI-1 activity
was detected in virtually all uPA2/2, tPA2/2, and
utPA2/2 End. cell lines (Table II).
Morphogenetic Behavior of Mutant End. Cells in
Fibrin Gels
We have previously reported that End. cells form large
cystlike structures lined by a monolayer of endothelial
cells when embedded in three-dimensional fibrin gels in
vitro (Montesano et al., 1990). In the present study we
have observed that although all six wild-type cell lines
have the capacity to form cysts in fibrin gels, there is het-
erogeneity with respect to the size of the cysts and the fre-
quency with which they form. In addition to cysts, the
presence of narrow or ectatic tubes was observed in four
out of six lines (Fig. 4 and Table II). When grown in fibrin
gels in the presence of Trasylol, a broad-spectrum serine
protease inhibitor, cyst formation was inhibited and tube-
like structures were observed in most wild-type End. cell
lines (Fig. 4 and data not shown).
Both uPA2/2 cell lines (u23 and u24) retained their ca-
pacity to form medium to small cysts (Fig. 4 and Table II).
Cyst formation was completely inhibited in the presence
of Trasylol, demonstrating the requirement for serine pro-
tease activity (data not shown). However, in contrast with
wild-type cells, tube formation was never observed in the
presence of Trasylol in either uPA2/2 cell line; instead
these cells either formed multicellular aggregates or re-
mained as single isolated cells (data not shown). The two
tPA2/2 cell lines (t37 and t38) formed small cysts and oc-
casional tube-like structures (Fig. 4 and Table II). Cyst
and tube formation could be prevented by addition of Tra-
sylol to t37 but not to t38 cells (data not shown). In striking
contrast with most of the cell lines described thus far, both
utPA2/2 cell lines (ut1 and ut2) completely lost their ca-
pacity to form cysts (Fig. 4 and Table II). In addition, two
clearly distinguishable cell populations could be identified:
cells either organized into a network of cell cords or re-
mained isolated as single rounded cells (Fig. 4 and Table
II). Finally, PAI-1Ðdeficient cells formed cysts, although in
later passage p1 cells, rapid and massive fibrinolysis pre-
cluded the formation of either cysts or tubes (Fig. 4 and
Table II). p3 cells appeared to be heterogeneous: in early
passage cells, two cell populations that either formed cysts
or cell cords could be identified. Cyst formation (in p1 and
p3 cells) and fibrinolysis (in late passage p1 cells) could be
inhibited by Trasylol. Cell cord formation by ut1, ut2, and
p3 cells was unaffected by addition of Trasylol (data not
shown). These findings show that, contrary to what might
have been expected, uPA2/2 and PAI-12/2 cells do not
display a decreased or increased capacity to form cysts.
The observation that the capacity to form cysts was re-
duced to a greater extent in tPA2/2 cells than in uPA2/2
cells suggests that, although both enzymes are capable of
fibrinolysis in this system, tPA is more efficient. 
Tumorigenic Potential of uPA-,
tPA-, and utPA-deficient End. Cells in Adult
Wild-Type Mice
To define a causal role for the PAs in End. cellÐinduced
vascular tumors, we have used cells lacking uPA, tPA, and
both uPA and tPA (utPA) for tumor formation studies in
adult wild-type mice. We have used immunologically com-
petent adult mice in these studies to avoid variability that
may arise from the use of newborn mice with a developing
immune system. Tumors were visible as small outgrowths
in all mice injected with wild-type End. cells between day 4
and 7 and grew in size to 125 mm2 by 11Ð18 d (Fig. 5 A).
Histologically, these tumors consisted of a central hemor-
rhagic/necrotic core surrounded by an intense inflamma-
tory cell infiltrate with neovascularization and very little
fibrin deposition (Fig. 6, A and B). Similar results were ob-
tained in mice injected with tPA-deficient End. cells, and
there was no significant delay in either the onset or growth
rates of these tumors. In contrast, tumor induction with
uPA2/2 End. cells showed incomplete penetrance and a
delay in formation (Fig. 5 A). Only 50% of the mice devel-
oped tumors by days 11Ð14, and it took between 18 and 25 d
for these tumors to reach maximum size. The remaining
mice did not develop tumors for the entire 60-d observa-
tion period. Similarly, about two-thirds of the mice in-
jected with End. cells deficient in both uPA and tPA de-
veloped tumors at an extremely slow rate (Fig. 5 A).
Tumors were visible between 19 and 24 d after injection,
and it took between 40 and 60 d to form tumors of maxi-
mum size. The remaining mice did not develop tumors.
Histologically, these tumors were similar to those induced
by wild-type cells, with the notable exception that exten-
sive fibrin deposition was observed with the Lendrum and
PTAH staining techniques (Fig. 6, E and F; data not
shown). These results indicate that End. cell lines lacking
only tPA activity are not inhibited in their capacity to form
tumors. However, cell lines lacking uPA activity (both
uPA2/2 and utPA2/2) display a reduced efficiency in
tumor formation in wild-type mice; when tumors do arise,
their growth rate is significantly retarded, indicating that
uPA activity of tumor cells is critical for efficient tumor
growth.
To rule out the possibility that the observed differences
in tumor formation rates were due to various degrees of
histoincompatibility, we performed the tumor formation
studies in immunoincompetent nude mice. After injection
of wild-type and tPA2/2End. cells, tumors were visible
around day 5 and grew in size to 125 mm2 by 10Ð11 d (Fig.
5 A). In contrast, tumors were only visible between 7 and
14 d after injection with uPA2/2 End. cells, and these tu-
mors grew in size to 125 mm2 by 18Ð22 d (Fig. 5 A). Similar
results were obtained when utPA2/2 End. cells were
used, with tumors being visible between 10 and 14 d and
reaching maximum size by 22Ð26 d (Fig. 5 A). These re-
sults in immunoincompetent mice confirm that the lack of
tPA activity in End. cell lines does not affect their tumori-
genic potential, whereas lack of uPA activity retards theSabapathy et al. PymT Oncogenesis and the Role of PA/Plasmin System 959
tumorigenic potential of both uPA2/2 and utPA2/2
End. cell lines.
Tumor Induction by Wild-Type and Mutant End. Cells 
in Adult uPA-, tPA-, and utPA-deficient Mice
We next investigated if adult mice lacking uPA, tPA, or
both utPA are susceptible to tumor induction by wild-type
End. cells. Cells were inoculated into the various mutant
mice and tumor growth rates were scored (Fig. 5 B). No
significant delay was observed in the onset of tumor devel-
opment in tPA-deficient mice when compared with wild-
type controls, although the time taken to reach maximum-
sized tumors was slightly delayed (between 14 and 20 d in
tPA-deficient mice as compared with 11Ð18 d in wild-type
mice). However, tumor growth was delayed and variation
Figure 5. Incidence and latency of tumor formation. End. cellÐ
induced tumor formation was investigated using mutant End.
cells in wild-type and nude mice (A), wild-type End. cells in mu-
tant mice (B), and utPA2/2 End. cells in mutant mice (C). All
mice were inbred for more than six generations and injected with
the following cell lines; the time taken for the onset of tumors
(days after injection) and the latency period for the formation of
125-mm2 tumors was recorded: wild-type, s1 (p35 and 40) and s2
(p23, 34 and 40); uPA2/2, u23 (p33) and u24 (p23); tPA2/2, t37
(p25 and 35) and t38 (p6 and 25); and utPA2/2, ut1(p20) and ut2
(p28 and 40). Observation period was for up to 60 d after injec-
tion. n, number of mice from at least two independent experi-
ments.The Journal of Cell Biology, Volume 137, 1997 960
Figure 6. Morphology of End. cellÐinduced tumors in wild-type and mutant adult mice. (A) s1-induced subcutaneous tumor in a wild-
type mouse after 3 d; B is the consecutive section stained with the Lendrum technique: note the absence of fibrin deposition, (C) b3-
induced subcutaneous tumor in a tPA2/2 mouse, and (D) s2-induced tumor in a uPA2/2 mouse after 3 d. Note the presence of a cen-Sabapathy et al. PymT Oncogenesis and the Role of PA/Plasmin System 961
in tumor formation rates was observed in uPA-deficient
mice as follows: (a) only 3 out of 11 uPA-deficient mice
developed tumors 12 to 14 d after injection, which grew to
maximum size by day 27; (b) tumors were also visible in
two other uPA-deficient mice between 12 and 14 d, but
these tumors subsequently regressed; (c) the remaining six
mice did not develop tumors throughout the entire 60-d
observation period. Of the utPA-deficient mice injected
with wild-type cells, only two out of four had visible tu-
mors 18Ð20 d after injection, which then progressed to 125-
mm2 tumors by days 40Ð50. The remaining two mice did
not develop tumors for the entire observation period.
Only four utPA2/2 mice could be used in this study since
most of these mutant mice, even uninjected, became ill as
they grew older (Carmeliet et al., 1994). Histologically, tu-
mors induced by wild-type cells in mutant mice (Fig. 6, C
and D) were similar to those induced in wild-type mice
(Fig. 6, A and B), both at early (3 d; Fig. 6, C and D) and
late (27 d; Fig. 6 G) time points. However, tumors induced
by wild-type cells in utPA2/2 mice were consistently associ-
ated with extensive fibrin deposition, as seen using the
Lendrum and PTAH staining techniques (Fig. 6 H and
data not shown). These results indicate that the hostÕs PA
status, and in particular the presence of uPA activity, plays
a critical role in determining if proteolytically competent
tumor cells can proliferate in vivo.
Since lack of uPA activity in both the host and the in-
jected tumor cells affected the efficient formation of tu-
mors, we next investigated the potential of utPA2/2 End.
cells to form tumors in mice lacking either uPA or tPA.
Tumor formation by utPA2/2 End. cells was inhibited in
tPA2/2 mice, since only three of the seven tPA2/2 mice
initially developed tumors between days 16 and 21; how-
ever, these tumors regressed by day 40 in all cases (Fig.
5 C). The remaining mice remained tumor free. utPA2/2
End. cells did not form tumors in any of the uPA2/2 mice
during the entire observation period (Fig. 5 C). These re-
sults suggest that, although the lack of tPA alone has no
significant effect on tumor formation, the uPA status of
both the host and invading tumor cell has an important
role in determining the progression of End. cell tumors.
Discussion
The specific formation of vascular tumors by PymT anti-
gen provides an excellent system to study the molecular
mechanisms underlying endothelial cell transformation. One
of the components of this process is extracellular matrix
degradation and invasion of surrounding tissues, which in
the case of PymT results in a profound subversion of nor-
mal vasculature. In an attempt to analyze the role of the
PA/plasmin system in PymT-mediated oncogenesis, we
have investigated its ability to transform endothelial cells
in mice lacking uPA, tPA, both uPA and tPA (utPA), or
Plg. We found that the proteolytic status (PA/plasmin sys-
tem) is not a critical determinant, and hence is not limiting
for PymT-induced tumor formation. Moreover, the lack of
either uPA or tPA activity does not affect the establish-
ment of End. cells in vitro, although the combined loss of
both PA activities leads to a reduced proliferation rate.
Cyst formation by End. cells in fibrin gels in vitro could be
correlated with altered proteolytic activity only in cells
lacking uPA and tPA. However, End. cellÐinduced tumor
formation in vivo, as opposed to tumors induced by PymT
itself, is dependent on the proteolytic status (PA/plasmin
system) of both the tumor cells and the host.
The finding that PymT was able to induce vascular tu-
mors efficiently in the absence of uPA, tPA, utPA, and Plg
indicates that the primary transformation process is inde-
pendent of the PA/plasmin proteolytic status of the endo-
thelial cells. This suggests that PymT-induced tumors can
only be used as an in vivo assay for determining the role of
this oncogene and associated signaling components in the
initial transformation process. To date, the only signaling
molecule thus identified is the Src-like kinase, Yes, since
PymT could not efficiently transform endothelial cells in
Yes-deficient mice in which the latency for tumor forma-
tion was also increased (Kiefer et al, 1994b).
Mutant End. cells lacking either uPA or tPA show no pro-
liferation defect in culture. However, End. cell lines lack-
ing both uPA and tPA require a longer time for establish-
ment (three times longer compared with wild-type End.
cells) and, when established, exhibit a marked reduction in
cell proliferation in vitro. This proliferation defect is also
exemplified in End. cellÐinduced tumor formation in vivo
where cells lacking both PAs do not form tumors effi-
ciently, and, when they do, the time taken to reach maxi-
mum size is about three times that seen with wild-type
End. cells.
Assessment of the morphogenetic behavior of mutant
End. cells in fibrin gels in vitro revealed that, although
tPA appeared to be more efficient, the absence of either
uPA or tPA alone did not render End. cells incapable of
forming cysts, indicating that one PA is sufficient. How-
ever, combined loss of both uPA and tPA prevented cyst
formation, clearly indicating that PA activity is required.
The previous prediction that the Òproteolytic balance,Ó as
represented by the ratio of PA:PAI-1, would predict the
behavior of End. cells in fibrin gels (Montesano et al.,
1990) therefore appears to hold true only when both PAs
are absent. These findings indicate that the in vitro system
only partially mimics the in vivo situation, and that the be-
havior of End. cells in fibrin gels is a poor predictor of
End. cell tumorigenesis.
The incidence and rate of tumor formation in wild-type
mice using End. cells lacking tPA activity were not signifi-
tral hemorrhagic/necrotic core surrounded by extensive peritumoral host cell recruitment (including inflammatory cells) and neovascular-
ization in all sections (AÐD) irrespective of cell or mouse genotype at this early time point (3 d). (E) ut1-induced tumor in a wild-type
mouse after 40Ð45 d. (F) The consecutive section from the same tumor (which has been rotated slightly): staining with the Lendrum
technique reveals extensive fibrin deposition, (G) s2-induced tumor in a uPA2/2 mouse after 27 d, (H) s2-induced tumor in a utPA2/2
mouse after 30 d; staining with the PTAH technique reveals extensive fibrin deposition. Note the persistence of peritumoral host cell re-
cruitment in all sections (EÐH) irrespective of cell or mouse genotype at this late time point (27Ð45 d). All sections stained with hema-
toxylin and eosin unless otherwise stated. Bar, 170 mm.The Journal of Cell Biology, Volume 137, 1997 962
cantly affected. However, there was a marked decrease in
the number of mice that developed tumors when injected
with uPA2/2 and utPA2/2 End. cells. When tumors did
form in a subset of these mice, the onset was delayed and
the time taken to develop to maximum size was increased.
In some cases, mice developed tumors initially, but these
subsequently regressed completely. The data from tumor
formation studies with nude mice ruled out the possibility
that various degrees of histoincompatibility may have
arisen during the establishment or the maintenance of
mouse strains and tumor cell lines, thus affecting the ex-
perimental outcome. While wild-type and tPA2/2 cell
lines still formed tumors with 100% penetrance in nude
mice, both uPA2/2 and utPA2/2 End. cell lines showed
a delay in the onset of tumor formation as well as an in-
crease in the time taken to form 125-mm2 tumors. Further-
more, we have previously generated numerous End. cell
lines lacking functional c-src, fyn, and yes genes in the
same genetic background, C57Bl/6 3 129. These cell lines
have been used in similar tumorigenicity studies, and no
variations in the tumorigenic profile were found (Kiefer et
al., 1994). Thus, the observed delay in End. cellÐinduced
tumor formation and the consequent low incidence of tu-
mor-bearing mice are not likely to result from genetic vari-
ations but could be from inefficient matrix degradation
and a reduction in migratory/invasive properties of the tu-
mor cells, which in turn lead to inefficient tumor expan-
sion. This observation that End. cellÐinduced tumors can-
not be efficiently formed when endogenous uPA is lacking
but are independent of tPA may reflect the longstanding
notion that uPA is required in situations of cell migration,
morphogenesis, and tissue remodeling, while tPA is prima-
rily implicated in intravascular thrombolysis.
The finding that mice lacking uPA activity (both uPA
and utPA null mice) do not display efficient formation of
wild-type End. cellÐinduced tumors was surprising. There
was a marked decrease in the formation of tumors, and,
when formed, there was a delay in the onset and latency.
This indicates that the hostÕs proteolytic status is also criti-
cal for the efficient formation of these tumors. Although
the exact role of the hostÕs uPA activity in tumor forma-
tion is presently unclear, it could be envisaged that the
uPA proteolytic mechanism has to involve concerted in-
teractions between both the invading tumor cells and the
hostÕs matrix for efficient fibrinolysis and subsequent ma-
trix degradation. Thus, the lack of uPA activity in either
would result in inefficient colonization by the tumor cells,
as was shown here.
In conclusion, our studies have revealed that the patho-
genesis of PymT-induced and End. cellÐinduced tumors is
inherently different. In the former, the PymT virus infects
endothelial cells in an existing vascular tree without the re-
quirement for the PA/plasmin system in the initial trans-
formation process (Fig. 7 A). Therefore, PymT-mediated
vascular tumor formation appears to be PA/plasmin inde-
pendent. On the other hand, in End. cellÐinduced tumors,
the injected cells first have to invade host tissues and the
basement membrane of existing blood vessels to gain ac-
cess to the circulation to integrate within host vessels. This
invasive process, which is reminiscent of tumor cell intra-
vasation into the vascular tree, is dependent on both the
hostÕs and invading tumor cellÕs PA/plasmin status (Fig.
7 B). In addition, proliferation is impaired in cells entirely
lacking PA activity. Defects in both invasion and prolifera-
tion, both of which appear to be PA dependent, are there-
fore likely responsible for the reduction in End. cellÐinduced
tumor growth. Whether other proteases such as the MMPs,
which have been shown to be involved in vascular tumor
formation in vivo (Taraboletti et al., 1995), may play a role
in this process has to be investigated in future experi-
ments.
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